Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
An NTP binding site is a type of binding site found in nucleoside monophosphate (NMP) kinases, N can be adenosine or guanosine. A P-loop is one of the structural motifs common for nucleoside triphosphate (NTP) binding sites, it interacts with the bound nucleotide's phosphoryl groups. For the binding site to be able to bind a nucleotide, the nucleotide must be complex bound to Mg2+ or Mn2+. Nucleotide binding will cause conformational changes in the protein because the P-loop will bend. NTP binding sites play a role in poliovirus RNA replication. On the poliovirus RNA-dependent polymerase, also known as 3Dpol, there are two binding sites. Both binding sites contain lysine residues; however, only the lysine at position 61 is essential for RNA sequence elongation as part of the replication process. Additionally, a method known as computational alanine mutagenesis, has been used to find the key portions within the amino acid sequences that majorly characterize a particular NTP binding site; these regions within the sequence are conserved.
Barium is formed in large amounts by the fission process. A short-lived barium isotope was confused with radium by some early workers. They were bombarding uranium with neutrons in an attempt to form a new element. But instead they caused fission which generated a large amount of radioactivity in the target. Because the chemistry of barium and radium the two elements could be coseparated by for instance a precipitation with sulfate anions. Because of this similarity of their chemistry the early workers thought that the very radioactive fraction which was separated into the "radium" fraction contained a new isotope of radium. Some of this early work was done by Otto Hahn and Fritz Strassmann.
24 April Astronomers release close-up global images, for the first time, of the Martian moon Deimos that were taken by the Mars Hope orbiter. The first review of issues identified in meta-science of metascience is published, providing an overview of ten "questionable" practices (QMPs) in the field such as "overplaying the role of replication in science" and preregistration potential. A policy study identifies reduction of car travel activity as the most important transportation policy option in reducing GHG emissions to levels comparable to carbon budget levels, with a "decrease car distance driven and car ownership by over 80% as compared to current levels" by 2027 being effective in "edging close to the designated carbon budget" in their case-study of London and electrification being highly insufficient. On 20 April, an international study indicates that the contemporary domestic policy-proposal of a general speed limit on highways in Germany, the only large country in the world without such, for a quick GHG emissions reduction would also be economically beneficial. It points to a climate change mitigation law (KSG) that mandated emission reductions in this sector that was changed in 2023 so as to remove these obligations. 25 April Scientists, based on new evidence, conclude that Rosalind Franklin was a contributor and "equal player" in the discovery process of DNA, rather than otherwise, as may have been presented subsequently after the time of the discovery.
==== Diagnosis ==== A bone mineral density test, such as dual-energy X-ray absorptiometry, is commonly used to assess bone strength, particularly in the hip and spine. Screening is generally recommended for women aged 65 and older, postmenopausal women with risk factors, and some men based on clinical evaluation.
Sources: en.wikipedia.org
==== Human evolution ==== During the long period between one and three million years ago, the Australopithecine (ancestors of modern humans) underwent several evolutionary changes. A long-term climate shift toward drier conditions promoted life changes from sedentary forest-dwelling with a primarily plant-based diet toward upright walking/running on open terrain and more meat consumption. One consequence of the shift to a culture that included more physically active hunting was a need for evaporative cooling from sweat, which to be functional, meant an evolutionary shift toward less body hair, as evaporation from sweat-wet hair would have cooled the hair but not the skin underneath. A second consequence was darker skin. The early humans who evolved in the regions of the globe near the equator had permanent large quantities of melanin in their skin, resulting in brown/black skin tones. For people with light skin tone, exposure to UV radiation induces the synthesis of melanin causing the skin to darken, i.e., sun tanning. Either way, the pigment can protect skin by dissipating up to 99.9% of absorbed UV radiation. In this way, melanin protects skin cells from UVA and UVB radiation damage that causes photoaging and the risk of melanoma, a cancer of melanin cells. Melanin also protects against photodegradation of the vitamin folate in skin tissue and, in the eyes, preserves eye health. The dark-skinned humans who had evolved in Africa populated the rest of the world through migration some 50,000 to 80,000 years ago.
malnutrition and vitamin deficiency immunodeficiency poor oral hygiene recent illness (especially acute necrotizing ulcerative gingivitis, measles, malaria, or kwashiorkor), social and environmental factors such as maternal malnutrition and closely spaced pregnancies that result in offspring with weakened immune systems In 2026 a newly discovered bacterium, Treponema A, was found in tissue samples from current sufferers of the disease as well as in historic samples. Further research is needed to establish if this could be a causative factor.
=== Shock, tilt, and vibration monitoring === Shock indicators, tilt indicators, and vibration monitors can be attached to products, packages, pallets, or shipping containers. They show or record when handling conditions exceed a selected limit. Digital data loggers can record the magnitude, direction, duration, and timing of shocks and vibrations. The collected information may support product inspection, carrier evaluation, damage investigation, and laboratory package testing. These systems are used with medical equipment, calibrated instruments, electronics, artworks, industrial components, and other sensitive goods.
=== Vegetarian HDR and MARC === The Humanitarian Daily Ration (HDR) is a self-contained Halal meal designed to be given to refugees and other displaced people. It is designed to feed a person for a full day, and the menus are intended to be palatable to many religious and cultural tastes. To meet this goal, no animal products or by-products, no alcohol or alcohol-based products, and minimal dairy products are used in their production. It is otherwise created and packaged much like MREs; feedback from the Afghanistan campaign led to the interior packing being reinforced to withstand being air-dropped, as the packets sometimes ruptured on impact. The outer bag is tinted a high-visibility red or yellow and has an American flag and a picture of a person eating out of the bag with a spoon. There are usually instructions printed on it in English and one or more local languages as well. The Meal, Alternative Regionally Customized (MARC) is a self-contained, shelf-stable meal developed by U.S. Army Soldier and Biological Chemical Command (SBCCOM)/Natick, Individual Combat Ration Team (ICRT), Combat Feeding Directorate (CFD). MARCs were developed specifically for detainees at Guantanamo Bay, and have since found wider spread use, notably Iraq and Afghanistan. MARC meals are entirely vegetarian as an easy way to prevent conflicts with culturally "prohibited products" (Islam and Judaism forbidding pork, Hindus avoiding beef, etc). They are neither Kosher nor Halal certified.
==== MeSH D08.811.600 – multienzyme complexes ==== MeSH D08.811.600.075 – anthranilate phosphoribosyltransferase MeSH D08.811.600.085 – anthranilate synthase MeSH D08.811.600.116 – aspartate carbamoyltransferase MeSH D08.811.600.130 – aspartokinase homoserine dehydrogenase MeSH D08.811.600.200 – cholesterol side-chain cleavage enzyme MeSH D08.811.600.250 – electron transport chain complex proteins MeSH D08.811.600.250.500 – electron-transferring flavoproteins MeSH D08.811.600.250.500.500 – electron transport complex i MeSH D08.811.600.250.500.750 – electron transport complex ii MeSH D08.811.600.250.500.750.500 – succinate dehydrogenase MeSH D08.811.600.250.687 – electron transport complex iv MeSH D08.811.600.250.875 – succinate cytochrome c oxidoreductase MeSH D08.811.600.250.875.249 – electron transport complex ii MeSH D08.811.600.250.875.249.500 – succinate dehydrogenase MeSH D08.811.600.250.875.500 – electron transport complex iii MeSH D08.811.600.317 – fatty acid synthetase complex MeSH D08.811.600.391 – glycine decarboxylase complex MeSH D08.811.600.391.100 – aminomethyltransferase MeSH D08.811.600.391.150 – dihydrolipoamide dehydrogenase MeSH D08.811.600.391.175 – glycine decarboxylase complex h-protein MeSH D08.811.600.391.200 – glycine dehydrogenase (decarboxylating) MeSH D08.811.600.465 – ketoglutarate dehydrogenase complex MeSH D08.811.600.465.500 – dihydrolipoamide dehydrogenase MeSH D08.811.600.541 – lactose synthase MeSH D08.811.600.700 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.600.710 – photosynthetic reaction center complex proteins MeSH D08.811.600.710.249 – light-harvesting protein complexes MeSH D08.811.600.710.374 – cytochrome b6f complex MeSH D08.811.600.710.374.500 – cytochromes b6 MeSH D08.811.600.710.374.750 – cytochromes f MeSH D08.811.600.710.374.875 – plastoquinol-plastocyanin reductase MeSH D08.811.600.710.500 – photosystem i protein complex MeSH D08.811.600.710.750 – photosystem ii protein complex MeSH D08.811.600.715 – polyketide synthases MeSH D08.811.600.720 – prostaglandin-endoperoxide synthases MeSH D08.811.600.720.500 – cyclooxygenase 1 MeSH D08.811.600.720.750 – cyclooxygenase 2 MeSH D08.811.600.730 – proteasome endopeptidase complex MeSH D08.811.600.741 – pyruvate dehydrogenase complex MeSH D08.811.600.741.525 – dihydrolipoamide dehydrogenase MeSH D08.811.600.741.625 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.600.741.725 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.600.850 – sucrase-isomaltase complex MeSH D08.811.600.896 – tryptophan synthase
Sources: en.wikipedia.org
== Function == The protein encoded by this gene is the predominant constituent of the crystalline core of the eosinophil granule. High levels of the proform of this protein are also present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT), and C3dg. This protein may be involved in antiparasitic defense mechanisms as a cytotoxin and helmintho-toxin, and in immune hypersensitivity reactions. It is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases. PRG2 is a 117-residue protein that predominates in eosinophil granules. It is a potent enzyme against helminths and is toxic towards bacteria and mammalian cells in vitro. The eosinophil major basic protein also causes the release of histamine from mast cells and basophils, and activates neutrophils and alveolar macrophages.
Dinosterol has been used as a biomarker for dinoflagellates whose sedimentary concentration has been correlated with changes in marine production rates. In a study by Schubert et al., it was shown that dinosterol has a concordant concentration maximum that coincides with organic carbon maxima over the past 200,000 years in a sediment core from the northeastern Arabian Sea. In this study, dinosterol was used to trace changes in ocean production in the Arabian Sea. Due to similar distributions of dinosterol and brassicasterol, a biomarker indicative of diatom abundances, it was concluded that the relative contributions of the dominant members of the phytoplankton community to production were uniform on timescales greater than 3,000–4,000 years over the past 200,000 years, despite overall paleoproduction having changed dramatically. Cross-spectral analysis of overall marine production (Corg) and biomarkers, dinosterol and brassicasterol, show very high spectral coherencies, supporting the correlation between Corg and dinosterol.
For services to Social Enterprise and the Creative Industries. Ivora Maria Ferreria-Bean. Team Manager, Birmingham Children's Trust. For services to Children and Families. Malcolm Ernest Ferris-Lay. Trustee, Tea Trade Benevolent Society and Scottish Tartan Authority. For Charitable Service. Maxine Jane Ficarra (Maxine Purdie). Lately Chief Executive Officer, PraxisAuril. For services to Knowledge Exchange. Margaret Ruth Fingerhut. For services to Music and to Charitable Fundraising. David Edward Clarke Finlay. For services to Olympic Wrestling in Northern Ireland. Stephen Fischbacher. Founding Director, Fischy Music. For services to Mental Health and Well-Being. Alison Fordy. Proprietor, Alison Radcliffe School of Dance. For services to Young People and to the community in Middlesbrough, North Yorkshire. Alison Fotheringham. Appeals and Litigation Assistant Director, Home Office. For Public and Voluntary Service. Alison Jane France. Operational Leader, Department for Work and Pensions. For services to Disadvantaged People. Susan Elizabeth Francis. Principal Educational Psychologist and Strategic Lead for Children and Young People's Emotional Wellbeing and Mental Health, Enfield London Borough Council. For services to Children with Special Educational Needs and Disabilities. Mike Anthony Frankl. For services to Charity, to Homeless People and to the Jewish Community in Cambridge. Pamela Marguerita Frickleton. Foster Carer, Plymouth City Council. For services to Young People. Peter Thornton Frickleton. Foster Carer, Plymouth City Council. For services to Young People.
=== 1971-2000 === In 1971, Revlon acquired DCL BioMedical, a clinical laboratory business founded in 1968. In 1974, it changed its name to National Health Laboratories Incorporated. By 1977, it operated clinical testing laboratories in 13 cities and maintained auxiliary service centers and satellite laboratories in 15 other cities. In 1978, it acquired American Biomedical Corporation, giving it operations in the Southwestern United States and data processing technology. In 1985, Revlon was acquired by Ronald Perelman. Revlon divested its other businesses and a major stake in the company was acquired by MacAndrews & Forbes. In 1988, National Health Laboratories became a public company via an initial public offering on the NASDAQ exchange. In 1989, the company generated revenue of about US$400 million, with about US$70 million in earnings. In the early 1990s, worries about malpractice lawsuits led doctors to conduct more clinical testing before diagnosing, which increased business for the company. In 1990, the company's revenues reached US$500 million, with over US$70 million in earnings. In 1991, National Health Laboratories moved its listing from the NASDAQ to the New York Stock Exchange. In June 1992, the company offered to acquire Damon Corporation for $260 million in cash and stock. However, the company was outbid by Corning Inc., which acquired Damon for $370 million. By 1993, the company had 22 major laboratories. On March 8, 1994, National Health Laboratories Inc. reorganized as a holding company, National Health Laboratories Holdings Inc.
== Use of methadone clinics internationally == Methadone clinics can provide methadone for on-site administration. Additionally, some methadone clinics provide the following: oversight of treatment, observed dosing, consultation services, urine drug test, naloxone distribution, mental health services, primary care services, and HIV and HCV services.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.